KOSDAQBiotech & Pharma388870

Pharos iBio

₩6,070▲ 1.17%2026-11-18 close
Market Cap
₩78.6B
Turnover
₩200M
Volume
30K
Shares out.
13M
PER
—
PBR
11.8×
EPS
-₩809
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

An AI drug developer without revenue, with licensing as the key test

Pharos iBio has yet to turn its Chemiverse-based drug candidates into licensing revenue, and operating losses and cash outflows continue.

  1. 1

    Only 2022 revenue of KRW 300 million appears in the filed annual figures; no revenue figures are presented for 2023 through 2025.

  2. 2

    Operating losses have run for four consecutive years from 2022 through 2025, with KRW 11.5 billion in 2025.

  3. 3

    The operating loss narrowed to KRW 1.99 billion in Q3 2026, within a run of five consecutive quarterly losses.

  4. 4

    The lead candidate PHI-101 has completed a global Phase 1 trial, and the company is holding licensing talks at BIO-Europe 2026 without any announced contract.

  5. 5

    The debt ratio rose to 114.5% at the end of 2025 from 5.5% in 2024, alongside a KRW 19 billion convertible bond issuance in December 2025.

02

Business structure

Pharos iBio was founded in 2016 and listed on KOSDAQ in 2023 as an AI-driven developer of drugs for rare and intractable diseases. Its proprietary Chemiverse platform covers the full development chain, from target discovery and candidate design to toxicity prediction and indication expansion.

The platform is built from more than nine AI modules. The company has no commercial product yet, and its business model relies on licensing deals and joint R&D with global pharmaceutical companies. Its main customers are pharmaceutical companies and medical institutions, and R&D spending is the main cost.

The core pipeline is PHI-101 (lasmotinib), a candidate for acute myeloid leukemia (AML) that has completed a global Phase 1 trial and is being prepared for Phase 2 and licensing in parallel. PHI-501, a candidate for intractable solid tumors, is in a Phase 1 trial in Korea.

PHI-701 was selected as the lead institution of a government R&D project from the Ministry of Health and Welfare, securing state R&D funding. A PHI-201 licensing deal signed with Yuhan in 2022 was terminated. Because there is no product revenue yet, a breakdown of revenue by segment is not yet meaningful. PHI-101 is positioned against gilteritinib, crenolanib and tuspetinib in the FLT3-targeted AML market.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3—-₩3B—
2025Q4—-₩2.9B—
2026Q1—-₩2.4B—
2026Q2—-₩2.3B—
2026Q3—-₩2B—
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩300M-₩10.6B-₩16.9B−3539.8%−95.5%6.0%
2023₩0-₩10.1B-₩8.9B—−31.5%4.7%
2024—-₩12.6B-₩10.4B—−55.6%5.5%
2025—-₩11.5B-₩10.7B—−76.8%114.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On the filed figures, the only revenue reported on an annual basis is KRW 300 million in 2022, and no revenue figures appear in the periodic reports for 2023 through 2025. The press reported zero revenue for 2023, 2024 and the first three quarters of 2025.

Operating losses were KRW 10.6 billion in 2022, KRW 10.1 billion in 2023, KRW 12.6 billion in 2024 and KRW 11.5 billion in 2025.

The filings describe 2023 as a continued loss with a smaller deficit, 2024 as a continued loss with a larger deficit, and 2025 as a continued loss with a smaller deficit, making four consecutive years of operating losses from 2022 through 2025.

The 2022 operating margin was -3,539.8%, meaning the loss far exceeded the small revenue base. Net loss attributable to controlling shareholders was KRW 16.9 billion in 2022, KRW 8.92 billion in 2023, KRW 10.4 billion in 2024 and KRW 10.7 billion in 2025.

Net loss including non-controlling interests was KRW 17.1 billion in 2022, KRW 8.86 billion in 2023, KRW 10.6 billion in 2024 and KRW 10.8 billion in 2025, a different measure from the controlling-shareholder figure.

Operating cash flow was -KRW 8.18 billion in 2022, -KRW 7.41 billion in 2023, -KRW 9.33 billion in 2024 and -KRW 8.35 billion in 2025. The debt ratio rose from 5.5% in 2024 to 114.5% in 2025.

At the end of 2025, total equity was KRW 13.9 billion, all of it attributable to controlling shareholders, and total liabilities were KRW 15.9 billion. This coincides with the KRW 19 billion convertible bond issued in December 2025.

On a quarterly basis, operating losses were KRW 2.99 billion in Q3 2025, KRW 2.94 billion in Q4 2025, KRW 2.37 billion in Q1 2026, KRW 2.28 billion in Q2 2026 and KRW 1.99 billion in Q3 2026, five consecutive quarterly losses with a narrowing deficit.

Net loss attributable to controlling shareholders was KRW 1.85 billion in Q3 2025, KRW 3.03 billion in Q4 2025 and KRW 2.22 billion in Q1 2026, and no figures are filed for Q2 or Q3 2026. The sum for the last four quarters, Q4 2025 through Q3 2026, is KRW 10.4 billion.

05

Industry analysis

The market Pharos iBio serves is the FLT3-targeted segment of AML treatment. Press reports state that FLT3 mutations are found in about 35% of AML patients. Existing FLT3-targeted drugs are limited by resistance mutations such as F691L, and the company says lasmotinib is being developed to suppress these.

Cross-trial comparisons are limited because study conditions differ. Even so, Money Today reported that lasmotinib's Phase 1b figures are higher than those of gilteritinib, crenolanib and tuspetinib.

An analyst at Valuefinder said growth in the menin inhibitor market could raise the value of lasmotinib as a combination partner. The company reported synergy with menin inhibitors and its selection for an investigator-led trial by WEHI in Australia.

Partnering events such as BIO-Europe and BIO USA are the main venues for licensing contact. Sisajournal wrote that future technology exports would be a key variable for corporate value and earnings improvement. Among AI drug platform companies, Pharos iBio emphasizes external validation of its platform.

06

Outlook

The company said it would attend BIO-Europe 2026 in Cologne, Germany, from November 9 to 11, 2026, to hold licensing talks on lasmotinib and PHI-501. The announcement described talks in plan form and did not report a signed contract.

Lasmotinib is in the stage of setting a development strategy for a Phase 2 trial after its global Phase 1 results. The company is pursuing a licensing target of KRW 1 trillion in total for PHI-501 at the Phase 1 stage, a company goal rather than a confirmed deal.

Lasmotinib has also been adopted for an investigator-led trial in patients with measurable residual disease, run simultaneously in Australia, New Zealand and the United States. In a November 5, 2026 announcement, the company said it would present combination data with menin inhibitors as a poster at ENA 2026.

PHI-501 is in a Phase 1 trial in Korea, and the company is expanding its indications to intractable lung cancer, colorectal cancer and malignant melanoma. PHI-701 is being developed as a fourth-generation EGFR inhibitor under a joint development memorandum with the pharmaceutical division of Kolon group.

The company said the KRW 19 billion convertible bond funds the Phase 2 entry for PHI-101 and later R&D, and it will weigh further fundraising against market conditions and R&D progress. The expiry at the end of 2025 of the exemption from delisting-related management designation is another financial checkpoint.

07

Valuation

PER
—
PBR
11.8×
ROE
-114.3%
EPS
-₩809
BPS
₩528
Dividend per share
₩0

Because cumulative net losses attributable to controlling shareholders over the last four quarters are negative, no earnings-based multiple is calculated. Dividend income is hard to expect from this company's structure.

The price-to-book ratio sits in a range with a large premium over net assets, and market capitalization is well above total equity of KRW 13.9 billion at the end of 2025. This can be read as the market pricing expectations for the pipeline and platform more than book capital.

Among biotech issuers, this company has no product revenue and is R&D-focused, so it is hard to compare on the same multiples used for listed companies with sales and profits. How one values book assets against pipeline value changes how the premium should be read.

On the filed trend, annual losses have stayed around KRW 10 billion to KRW 13 billion since 2023, and quarterly operating losses have narrowed through 2026. Since the convertible bond raised the debt burden, changes in the relationship between capital and losses should be tracked together.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

PHI-101 Phase 1 data against rival drugs

The company reported a composite complete remission rate of 50.0% and an objective response rate of 66.7% in the Phase 1b evaluable population of relapsed or refractory AML patients. Money Today reported that these figures exceed those of gilteritinib, crenolanib and tuspetinib.

Grade 3 or higher cardiotoxicity was reported at 0% throughout the trial. An analyst at Valuefinder described the data as a key negotiating asset in licensing talks with global pharmaceutical companies.

Pipeline diversification and combination strategy

The company is weighing combinations of lasmotinib with menin inhibitors, venetoclax and azacitidine, in addition to monotherapy. It said it will present combination research with a menin inhibitor as a poster at ENA 2026. PHI-501 has been in a Phase 1 trial in Korea since its first patient was dosed in January 2026.

PHI-701 was selected as lead institution of a Ministry of Health and Welfare national R&D project. The company stresses pipeline breadth so it does not depend on a single candidate.

Funding from state R&D and convertible bonds

State R&D funding tied to PHI-701 secured a total project budget of KRW 3.52 billion. In December 2025, the company completed a KRW 19 billion convertible bond issuance with investors including a private equity fund in which the National Pension Service took part.

The company said the proceeds will fund the PHI-101 Phase 2 entry and later R&D. It also said it is raising R&D efficiency through government projects, joint research and partnering.

09

Bear factors

No revenue and a missed IPO target

Press reports state that the company recorded zero revenue in 2023, 2024 and the first three quarters of 2025. At its IPO it targeted revenue above KRW 50 billion and a turn to profit in 2025, a goal it did not reach without licensing results.

The termination of the 2022 PHI-201 licensing deal with Yuhan eliminated milestone payments that had been expected from 2023 and 2024 research progress. The absence of new licensing contracts since listing is a weak point on the pace of commercialization.

Four straight years of losses and cash outflow

Operating losses are recorded as four consecutive years of losses from 2022 through 2025, with KRW 11.5 billion in 2025. Operating cash flow was -KRW 8.35 billion in 2025, and annual cash outflows have stayed in the KRW 7 billion to KRW 9 billion range.

Quarterly operating losses have narrowed, but with five consecutive quarterly losses through Q3 2026, no timing for a turn to profit has been set.

Higher debt ratio and thinner equity cushion

The debt ratio rose from 5.5% in 2024 to 114.5% in 2025. Total liabilities at the end of 2025 were KRW 15.9 billion, above total equity of KRW 13.9 billion. Total equity and the equity attributable to controlling shareholders are both KRW 13.9 billion, so annual losses keep reducing the capital base.

The expiry of the exemption from delisting-related management designation at the end of 2025 is another weak point.

10

Risk factors

Clinical uncertainty

Lasmotinib's response rates come from the patients evaluable for response. Phase 1 trials assess safety and early activity, and figures may change in Phase 2. PHI-501 is still in a Korean Phase 1 trial with no clinical data yet. Preclinical results do not guarantee clinical outcomes, so trial progress will determine licensing value.

Financing and listing requirements

The exemption from delisting-related management designation expired at the end of 2025. The company said it will carefully consider whether to raise funds when needed. With the debt ratio elevated, any new financing could dilute shareholders.

Continued negative operating cash flow means reliance on external funding persists unless licensing deals close.

Feasibility of licensing deals

Participation in BIO-Europe 2026 was described as a plan for talks and not a contract announcement. The KRW 1 trillion licensing target for PHI-501 is a company goal and not a confirmed deal. The earlier termination of the PHI-201 deal means the durability of licensing agreements also needs checking. Whether interest from global pharmaceutical companies turns into contract terms is not yet known.

11

What to watch next

  1. After December 2026 (timing not set)

    Whether a global Phase 2 entry for lasmotinib and any licensing contract are disclosed. If a contract is signed, its terms and upfront payment size should be checked.

  2. Late March 2027 (annual report filing deadline)

    Annual revenue, operating loss and operating cash flow in the 2026 annual report. The controlling-shareholder net loss figures for Q2 and Q3 2026 will also be confirmed.

  3. By May 15, 2027

    Operating loss trend in the Q1 2027 quarterly report. It will show whether the five-quarter losses continue and whether the narrowing trend holds.

  4. After December 2026 (timing not set)

    Whether interim results from the Korean Phase 1 trial of PHI-501 are released. The data could affect indication expansion and licensing talks.

12

Overall view

Pharos iBio is an R&D-focused company whose pipeline, including PHI-101 and PHI-501, is built on its Chemiverse AI platform. On the filed figures, no periodic-report revenue appears after KRW 300 million in 2022, and operating losses run for four consecutive years from 2022 through 2025.

The 2025 operating loss was KRW 11.5 billion, and operating cash flow was -KRW 8.35 billion. Quarterly operating losses narrowed to KRW 1.99 billion in Q3 2026, but this is the fifth consecutive quarterly loss.

PHI-101 reported a response rate that exceeds rival drugs in its global Phase 1 study, and licensing talks are underway. However, participation in BIO-Europe 2026 was a plan for talks, and no contract has been confirmed.

The debt ratio rose to 114.5% at the end of 2025, and the exemption from management designation has expired. The next checkpoints are the revenue and cash flow in the 2026 annual report and whether a Phase 2 entry or licensing contract for lasmotinib is disclosed.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. jobkorea.co.kr
  2. thevc.kr
  3. mt.co.kr
  4. saramin.co.kr
  5. biospectator.com
  6. sisajournal-e.com
  7. view.asiae.co.kr
  8. m.news.nate.com
  9. ibtomato.com
  10. newstap.co.kr
  11. medipana.com
  12. mt.co.kr
  13. medifonews.com
  14. kpanews.co.kr
  15. edaily.co.kr
  16. hankyung.com
  17. hankyung.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis